Abstract
Clinical studies using autologous CAR T cells have achieved spectacular remissions in refractory CD19+ B cell leukaemia, however some of the patient treatments with CAR T cells failed. Beside the heterogeneity of leukaemia, the distribution and senescence of the autologous cells from heavily pretreated patients might be further reasons for this. We performed six consecutive large-scale manufacturing processes for CD20 CAR T cells from healthy donor leukapheresis using the automated CliniMACS Prodigy® platform. Starting with a CD4/CD8-positive selection, a high purity of a median of 97% T cells with a median 65-fold cell expansion was achieved. Interestingly, the transduction rate was significantly higher for CD4+ compared to CD8+ T cells and reached in a median of 23%. CD20 CAR T cells showed a good specific IFN-γ secretion after cocultivation with CD20+ target cells which correlated with good cytotoxic activity. Most importantly, 3 out of 5 CAR T cell products showed an increase in telomere length during the manufacturing process, while telomere length remained consistent in one and decreased in another process. In conclusion, this shows for the first time that beside heterogeneity among healthy donors, CAR T cell products also differ regarding cell senescence, even for cells manufactured in a standardised automated process.
References
1.
Holzinger
A
, Barden
M
, Abken
H
. The growing world of CAR T cell trials: a systematic review
. Cancer Immunol Immunother
. 2016
Dec
;65
(12
):1433
–50
.
[PubMed]
0340-70042.
Hartmann
J
, Schüßler-Lenz
M
, Bondanza
A
, Buchholz
CJ
. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts
. EMBO Mol Med
. 2017
Sep
;9
(9
):1183
–97
.
[PubMed]
1757-46763.
Salmikangas
P
, Kinsella
N
, Chamberlain
P
. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Pharm Res
. 2018
May
;35
(8
):152
.
[PubMed]
0724-87414.
Abken
H
. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells
. Hum Gene Ther
. 2017
Nov
;28
(11
):1047
–60
.
[PubMed]
1043-03425.
Maude
SL
, Laetsch
TW
, Buechner
J
, Rives
S
, Boyer
M
, Bittencourt
H
, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
. N Engl J Med
. 2018
Feb
;378
(5
):439
–48
.
[PubMed]
0028-47936.
Kaiser
AD
, Assenmacher
M
, Schröder
B
, Meyer
M
, Orentas
R
, Bethke
U
, et al. Towards a commercial process for the manufacture of genetically modified T cells for therapy
. Cancer Gene Ther
. 2015
Mar
;22
(2
):72
–8
.
[PubMed]
0929-19037.
Priesner
C
, Aleksandrova
K
, Esser
R
, Mockel-Tenbrinck
N
, Leise
J
, Drechsel
K
, et al. Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs
. Hum Gene Ther
. 2016
. 1043-03428.
Mock
U
, Nickolay
L
, Philip
B
, Cheung
GW
, Zhan
H
, Johnston
IC
, et al. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy
. Cytotherapy
. 2016
Aug
;18
(8
):1002
–11
.
[PubMed]
1465-32499.
Gee
AP
. GMP CAR-T cell production
. Best Pract Res Clin Haematol
. 2018
Jun
;31
(2
):126
–34
.
[PubMed]
1521-692610.
Zhu
F
, Shah
N
, Xu
H
, Schneider
D
, Orentas
R
, Dropulic
B
, et al. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center
. Cytotherapy
. 2018
Mar
;20
(3
):394
–406
.
[PubMed]
1465-324911.
Lock
D
, Mockel-Tenbrinck
N
, Drechsel
K
, Barth
C
, Mauer
D
, Schaser
T
, et al. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use
. Hum Gene Ther
. 2017
Oct
;28
(10
):914
–25
.
[PubMed]
1043-034212.
Köhl
U
, Arsenieva
S
, Holzinger
A
, Abken
H
. CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications
. Hum Gene Ther
. 2018
May
;29
(5
):559
–68
.
[PubMed]
1043-034213.
Cawthon
RM
. Telomere measurement by quantitative PCR
. Nucleic Acids Res
. 2002
May
;30
(10
):e47
.
[PubMed]
0305-104814.
Melk
A
, Tegtbur
U
, Hilfiker-Kleiner
D
, Eberhard
J
, Saretzki
G
, Eulert
C
, et al. Improvement of biological age by physical activity
. Int J Cardiol
. 2014
Oct
;176
(3
):1187
–9
.
[PubMed]
0167-527315.
Jost
LM
, Kirkwood
JM
, Whiteside
TL
. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells
. J Immunol Methods
. 1992
Mar
;147
(2
):153
–65
.
[PubMed]
0022-175916.
Blaeschke
F
, Stenger
D
, Kaeuferle
T
, Willier
S
, Lotfi
R
, Kaiser
AD
, et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia
. Cancer Immunol Immunother
. 2018
Jul
;67
(7
):1053
–66
.
[PubMed]
0340-700417.
Gadalla
SM
, Aubert
G
, Wang
T
, Haagenson
M
, Spellman
SR
, Wang
L
, et al. Donor telomere length and causes of death after unrelated hematopoietic cell transplantation in patients with marrow failure
. Blood
. 2018
May
;131
(21
):2393
–8
.
[PubMed]
0006-497118.
Wang
C
, Zhang
T
, Wang
Y
, Li
Y
, Liu
C
, Liu
H
, et al. The shortening telomere length of T lymphocytes maybe associated with hyper‑function in servere aplastic anemia
. Mol Med Rep
. 2018
Jan
;17
(1
):1015
–21
.
[PubMed]
1791-300419.
Till
BG
, Jensen
MC
, Wang
J
, Qian
X
, Gopal
AK
, Maloney
DG
, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
. Blood
. 2012
Apr
;119
(17
):3940
–50
.
[PubMed]
0006-4971© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
